N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US-2017305847-A1 · Oct 26, 2017 · US
US10829445B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10829445-B2 |
| Application number | US-201916685534-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 15, 2019 |
| Priority date | Mar 17, 2006 |
| Publication date | Nov 10, 2020 |
| Grant date | Nov 10, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.
Opening claim text (preview).
What is claimed: 1. A method of preparing a compound of the formula (III) or a pharmaceutically acceptable salt thereof, wherein R 1 is H; R 2 is H; n is 0; b is an integer from 1 to 4; each R 8 is independently selected from halo, CF 3 , NO 2 , CN, phenyl, (C 1 -C 8 )alkyl, SO 2 NHOH, SO 2 CH 3 , SO 2 phenyl, C(O)O(C 1 -C 4 )alkyl, and C(O)morpholino; and Q 9 , Q 11 , Q 12 , Q 13 and Q 14 are defined such that ring C is furan or thiophene; the method comprising reacting a compound of formula A1 with hydroxylamine hydrochloride, wherein the compound of formula A1 has the structure: and R is furan or thiophene and is substituted with 1 to 4 R 8 . 2. The method of claim 1 , wherein, in the compound of formula (III), each R 8 is independently selected from F, Br, Cl, CF 3 , phenyl, methyl, SO 2 NHOH, and C(O)O(C 1 -C 4 )alkyl. 3. The method of claim 2 , wherein, in the compound of formula (III), R 8 is methyl and ring C is furan. 4. A method of preparing a compound of the formula (III) or a pharmaceutically acceptable salt thereof, wherein: R 1 is H; R 2 is H; n is 0; b is 1; R 8 is Cl, Br, nitro, methyl or cyano; and Q 9 , Q 11 , Q 12 , Q 13 and Q 14 are defined such that ring C is furan or thiophene; the method comprising reacting a compound of formula A1 with hydroxylamine hydrochloride, wherein the compound of formula A1 has the structure: and R is furan or thiophene and is substituted with 1 R 8 . 5. The method of claim 4 , wherein, in the compound of formula (III), R 8 is methyl and ring C is furan. 6. A method of preparing a compound which is: or a pharmaceutically acceptable salt thereof, the method comprising reacting a compound of formula A1 with hydroxylamine hydrochloride, wherein the compound of formula A1 has the structure: and is 3,5-dimethylisoxazole-4-sulfonyl chloride. 7. A method of preparing a compound which is: or a pharmaceutically acceptable salt thereof, the method comprising reacting a compound of formula A1 with hydroxylamine hydrochloride, wherein the compound of formula A1 has the structure: and is 1-methyl-1H-pyrazole-3-sulfonyl chloride. 8. A method of preparing a compound which is or a pharmaceutically acceptable salt thereof, the method comprising reacting a compound of formula A1 with hydroxylamine hydrochloride, wherein the compound of formula A1 has the structure: and is 4-bromothiophene-3-sulfonyl chloride, 3-bromothiophene-2-sulfonyl chloride, 4-bromo-2,5-dichlorothiophene-3-sulfonyl chloride or 4-phenyl-5-(trifluoromethyl)thiophene-3-sulfonyl chloride.
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2 · CPC title
with substituted hydrocarbon radicals attached to ring carbon atoms · CPC title
having nitrogen atoms of sulfonamide groups further bound to another hetero atom · CPC title
only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers · CPC title
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.